Seminar & Colloquium
[세미나: 8월 22일(화), 오전 11시] University of Michigan, Prof. JAMES J. MOON
Title
Engineering strategies to modulate the gut microbiome and immune system
Speaker
Prof. James J. Moon, University of Michigan
Education
- 1998 - 2002 B.S., Bioengineering, Univ. of California at Berkeley
- 2003 - 2008 Ph.D., Bioengineering, Rice University, Houston, TX.
- 2008 - 2012 Postdoctoral Associate, Materials Science & Engineering and Biological Engineering, MIT/HHMI, Cambridge, MA
Major Activities
- 2006 Summer research intern, Boston Scientific, Boston, MA
- 2008 - 2012 Postdoctoral Fellow, Howard Hughes Medical Institute, Prof. Darrell Irvine, MIT, MA
- 2012 - 2018 Assistant Professor, Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI
- 2012 - 2018 John Gideon Searle Assistant Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2012 - Core Member, Biointerfaces Institute, University of Michigan, Ann Arbor, MI
- 2012 - Member, Comprehensive Cancer Center, University of Michigan
- 2012 - Member, Michigan Nanotechnology Institute for Medicine and Biological Sciences
- 2016 - Member, Graduate Program in Immunology, University of Michigan
- 2016 - EVOQ Therapeutics, LLC. Co-Founder and Chief Scientific Officer
- 2018 - 2021 John Gideon Searle Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI(with tenure)
- 2018 - 2021 Associate Professor, Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI
- 2021 - Saros Therapeutics, LLC. Co-Founder and Chief Scientific Officer
- 2021 - J. G. Searle Professor, Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2021 - Professor, Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI
- 2021 - Professor, Department of Chemical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI
| Date | Tuesday, August 22nd, 2023
| Time | 11:00 ~
| Venue | 신소재공동 연구소(131동) 1층 (제 1세미나실)
[Abstract]
New approaches are needed to improve immunotherapies with minimal immune-related adverse events. The gut microbiome has recently emerged as the next frontier in drug development; however, it remains unclear how to effectively alter gut microbiota for treating various diseases, including cancer. Here, we present new biomaterial-based strategies for altering the gut microbiome and improving the safety and efficacy of cancer immunotherapy. We are developing new dietary fiber-based biomaterials for in situ modulation of the gut microbiome for augmenting local and systemic immune responses. Oral administration of inulin-gel in tumor-bearing mice in combination with anti-PD-1 immune checkpoint blockade led to robust anti-tumor efficacy while mitigating immune-related adverse events. In our second research thrust, we are developing a new nanoparticle platform for systemic delivery of STING (stimulator of IFN genes) agonists. While local STING activation can convert cold tumor into hot tumor, it has been challenging to develop STING agonists that can treat disseminated cancer due to their toxicity. Here, we will present our data showing that addition of manganese to STING agonists results in robust synergy. Lipid-based nanoparticles containing manganese and STING agonists allows for systemic cancer immunotherapy with potent efficacy, favorable pharmaceutical properties, and acceptable safety profiles in various murine and rabbit tumor models. Our biomaterial-based strategies may offer powerful and convenient approaches to regulate the immune system as potential therapies for cancer and other diseases.
| Host | 도준상 교수(02-880-1605)